Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.45 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.45 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.45 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.45 |
| ▸ | RAD52 | P43351 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7326006 | 0.98 | HRH3 (0.60) | HRH3CYP2C19CYP1A2SCN5ACARM1 | |
| SCHEMBL13766333 | 0.98 | HRH3 (0.52) | HRH3CYP2C19CYP1A2SCN5ACARM1 | |
| SCHEMBL13660804 | 0.96 | HRH3 (0.52) | HRH3CYP2C19CYP1A2SCN5ACARM1 | |
| SCHEMBL21727231 | 0.94 | HRH3 (0.52) | HRH3CYP2C19CYP1A2SCN5ACARM1 | |
| SCHEMBL9120834 | 0.94 | HRH3 (0.52) | HRH3CYP2C19CYP1A2SCN5ACARM1 | |
| SCHEMBL6733235 | 0.91 | CARM1 (0.48) | HRH3CYP2C19CYP1A2SCN5ACARM1 | |
| SCHEMBL13661321 | 0.90 | HRH3 (0.48) | HRH3CYP2C19CYP1A2SCN5ACARM1 | |
| SCHEMBL12612802 | 0.89 | CYP2C19 (0.52) | HRH3CYP2C19CYP1A2MEN1GLA | |
| SCHEMBL16675490 | 0.87 | HRH3 (0.47) | HRH3CYP2C19CYP1A2SCN5ACARM1 | |
| SCHEMBL13160710 | 0.86 | HRH3 (0.54) | HRH3SCN5ACARM1PRMT6PRMT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170137409-A1 | Amine Cationic Lipids and Uses Thereof | NOVO NORDISK A/S (DK) | 2017-05-18 | — | — | US | disclosed |
| US-9549983-B2 | Amine cationic lipids and uses thereof | DICERNA PHARMACEUTICALS, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20100222319-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-02 | — | — | US | disclosed |
| WO-2009131246-A1 | SORDARIN DERIVATIVES FOR PREVENTING OR TREATING INFECTIOUS DISEASES CAUSED BY PATHOGENIC MICROORGANISMS | ASTELLAS PHARMA INC. (JP) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137409-A1 | Amine Cationic Lipids and Uses Thereof | SGMS2, SLC43A1, SGMS1 | HRH3 454/4885CYP2C19 4871/4885CYP1A2 4850/4885 |
| US-20100222319-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | NNT, NAMPT, NQO1 | HRH3 1334/4885CYP2C19 849/4885CYP1A2 1022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.